Pharmacokinetics of 10-ethyl-10-deaza-aminopterin, edatrexate, given weekly for non-small-cell lung cancer

@article{Hartley1993PharmacokineticsO1,
  title={Pharmacokinetics of 10-ethyl-10-deaza-aminopterin, edatrexate, given weekly for non-small-cell lung cancer},
  author={Janet M. Hartley and Paul W. Nicholson and Ruth Allen and Peter Lamond and S. J. Harland and Robert L. Souhami},
  journal={Cancer Chemotherapy and Pharmacology},
  year={1993},
  volume={31},
  pages={328-332}
}
We studied the pharmacokinetics of 10-ethyl-10-deaza-aminopterin (10-EdAM), edatrexate and its 7-hydroxy metabolite during a phase II trial of treatment in advanced non-small-cell lung cancer. A dose of 80 mg/m2 was given weekly, with dose reduction being undertaken for mucositis or haematological toxicity. A triphasic pattern of plasma elimination was seen… CONTINUE READING